grade III glioma
diseaseOn this page
Also known as anaplastic gliomaWHO grade III glioma
Summary
grade III glioma (MONDO:0021640) is a cancer and 32 clinical trials. Top therapeutic interventions include flucytosine, isotretinoin, and lorlatinib. A subtype of malignant glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 32
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | grade III glioma |
| Mondo ID | MONDO:0021640 |
| NCIT | C127816 |
| UMLS | C4287997 |
| MedGen | 925529 |
| GARD | 0025346 |
| Is cancer (heuristic) | yes |
Also known as: anaplastic glioma · WHO grade III glioma
Disease family
This is a subtype of malignant glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › malignant glioma › grade III glioma
Related subtypes (11): spinal cord glioma, granular cell cancer, neurofibroma of gallbladder, neurofibroma of the heart, brain glioma, high grade astrocytic tumor, malignant perineurioma, malignant peripheral nerve sheath tumor, oligodendroglial tumor, isolated melanotic schwannoma, pediatric high-grade glioma
Subtypes (3): anaplastic oligodendroglioma, anaplastic ependymoma, anaplastic oligoastrocytoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 32.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1 | 10 |
| Not specified | 7 |
| PHASE1/PHASE2 | 3 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04623931 | PHASE2 | RECRUITING | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas |
| NCT05009992 | PHASE2 | RECRUITING | Combination Therapy for the Treatment of Diffuse Midline Gliomas |
| NCT05843253 | PHASE2 | RECRUITING | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant |
| NCT06161974 | PHASE2 | RECRUITING | Study of Olutasidenib and Temozolomide in HGG |
| NCT00555399 | PHASE1/PHASE2 | TERMINATED | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) |
| NCT00613093 | PHASE2 | COMPLETED | Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma |
| NCT00923117 | PHASE2 | TERMINATED | Sunitinib to Treat Recurrent Brain Cancer |
| NCT01200134 | PHASE2 | COMPLETED | HYPONCO - Hypoxia in Brain Tumors |
| NCT01434602 | PHASE1/PHASE2 | COMPLETED | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas |
| NCT01817751 | PHASE2 | COMPLETED | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma |
| NCT03914742 | PHASE1/PHASE2 | COMPLETED | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations |
| NCT04044937 | PHASE2 | COMPLETED | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms |
| NCT04482933 | PHASE2 | WITHDRAWN | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma |
| NCT02192359 | PHASE1 | ACTIVE_NOT_RECRUITING | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
| NCT02208362 | PHASE1 | ACTIVE_NOT_RECRUITING | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma |
| NCT03389230 | PHASE1 | ACTIVE_NOT_RECRUITING | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma |
| NCT03749187 | PHASE1 | ACTIVE_NOT_RECRUITING | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas |
| NCT04214392 | PHASE1 | ACTIVE_NOT_RECRUITING | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma |
| NCT04323046 | PHASE1 | RECRUITING | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults |
| NCT04540107 | PHASE1 | RECRUITING | Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma |
| NCT06253234 | PHASE1 | RECRUITING | Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas |
| NCT01172964 | PHASE1 | COMPLETED | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas |
| NCT03275558 | PHASE1 | WITHDRAWN | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma |
| NCT04135807 | EARLY_PHASE1 | RECRUITING | Implantable Microdevice In Primary Brain Tumors |
| NCT06333899 | EARLY_PHASE1 | RECRUITING | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion |
| NCT03244995 | Not specified | ACTIVE_NOT_RECRUITING | Mind-Body Intervention in Glioma Couples |
| NCT03251027 | Not specified | ACTIVE_NOT_RECRUITING | Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma |
| NCT04479696 | Not specified | RECRUITING | Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors |
| NCT05839379 | Not specified | RECRUITING | Targeted Pediatric High-Grade Glioma Therapy |
| NCT06975332 | Not specified | RECRUITING | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression |
| NCT00009035 | Not specified | COMPLETED | Natural History of Patients With Brain and Spinal Cord Tumors |
| NCT04630379 | Not specified | COMPLETED | Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUCYTOSINE | 4 | 1 |
| ISOTRETINOIN | 4 | 1 |
| LORLATINIB | 4 | 1 |
| OLUTASIDENIB | 4 | 1 |
| RIBOCICLIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| SUNITINIB | 4 | 1 |
| VALPROIC ACID | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| DORDAVIPRONE | 3 | 1 |
| CHLOROTOXIN | 2 | 1 |
| PAXALISIB | 2 | 1 |
| TASADENOTUREV | 2 | 1 |
| CHEMBL4228794 | 0 | 5 |
| CHEMBL4792718 | 0 | 1 |
| CHEMBL5439651 | 0 | 1 |
| CHEMBL4303155 | 0 | 1 |
| CHEMBL4436406 | 0 | 1 |
| CHEMBL5289235 | 0 | 1 |